Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.39 |
| ▸ | S100A4 | P26447 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2524312 | 0.86 | TDP1 (0.58) | TDP1SMN1; SMN2TSHRGPR35HSD17B10 | |
| SCHEMBL29132707 | 0.81 | GPR35 (0.48) | TDP1SMN1; SMN2TSHRGPR35L3MBTL1 | |
| SCHEMBL3450046 | 0.81 | TDP1 (0.44) | TDP1SMN1; SMN2TSHRGPR35HSD17B10 | |
| SCHEMBL30625900 | 0.80 | KMT2A (0.50) | TDP1SMN1; SMN2TSHRGPR35L3MBTL1 | |
| SCHEMBL601548 | 0.80 | KMT2A (0.50) | TDP1SMN1; SMN2TSHRGPR35L3MBTL1 | |
| SCHEMBL4151648 | 0.79 | TSHR (0.60) | TDP1SMN1; SMN2TSHRGPR35HSD17B10 | |
| SCHEMBL3631144 | 0.78 | MAPT (0.44) | TDP1SMN1; SMN2TSHRGPR35L3MBTL1 | |
| SCHEMBL102957 | 0.78 | MAPT (0.49) | TDP1SMN1; SMN2TSHRGPR35HSD17B10 | |
| SCHEMBL4725194 | 0.78 | TDP1 (0.48) | TDP1SMN1; SMN2TSHRGPR35HSD17B10 | |
| SCHEMBL944514 | 0.78 | TDP1 (0.44) | TDP1SMN1; SMN2TSHRHSD17B10L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340510-A1 | Substituted Phenylbenzenesulfonamide Derivatives and Uses Thereof | NINE SQUARE THERAPEUTICS CORPORATION (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250333399-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | KHORA SPV 1 LLC (US) | 2025-10-30 | — | — | US | disclosed |
| EP-4608389-A2 | SUBSTITUTED PHENYLBENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | Nine Square Therapeutics Corporation (US) | 2025-09-03 | — | — | EP | disclosed |
| US-20250223266-A1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2025-07-10 | — | — | US | disclosed |
| US-12331039-B2 | Inhibitors of fibroblast growth factor receptor kinases | KHORA SPV 1, LLC (US) | 2025-06-17 | — | — | US | disclosed |
| WO-2025096771-A1 | MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-05-08 | — | — | WO | disclosed |
| US-12129236-B2 | PARG inhibitory compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-10-29 | — | — | US | disclosed |
| CN-112979631-B | PARG inhibiting compounds | 癌症研究科技有限公司 | 2024-09-20 | — | — | CN | disclosed |
| WO-2024092235-A2 | SUBSTITUTED PHENYLBENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | NINE SQUARE THERAPEUTICS CORPORATION (US) | 2024-05-02 | — | — | WO | disclosed |
| CN-116057045-A | Fibroblast growth factor receptor kinase inhibitors | 金耐特生物制药公司 | 2023-05-02 | — | — | CN | disclosed |
| US-20200165208-A1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2020-05-28 | — | — | US | disclosed |
| US-20200165208-A1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2020-05-28 | — | — | US | disclosed |
| US-20180194738-A1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-07-12 | — | — | US | disclosed |
| US-20180194738-A1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-07-12 | — | — | US | disclosed |
| US-20180194738-A1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-07-12 | — | — | US | disclosed |
| EP-3233845-A1 | PARG INHIBITORY COMPOUNDS | Cancer Research Technology Limited (GB) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016097749-A1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016097749-A1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-06-23 | — | — | WO | disclosed |
| US-20080280933-A1 | BENZIMIDAZOLYL COMPOUNDS | EFREMOV IVAN | 2008-11-13 | — | — | US | disclosed |
| WO-2008012623-A1 | BENZIMIDAZOLYL COMPOUNDS AS POTENTIATORS OF MGLUR2 SUBTYPE OF GLUTAMATE RECEPTOR | PFIZER PRODUCTS INC. (US) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280933-A1 | BENZIMIDAZOLYL COMPOUNDS | PAICS, TMBIM6, ABCG2 | TDP1 3147/4885SMN1; SMN2 478/4885TSHR 2473/4885 |
| US-12331039-B2 | Inhibitors of fibroblast growth factor receptor kinases | FGFR1, FGFR2, FGFR3 | TDP1 2063/4885SMN1; SMN2 3037/4885TSHR 1346/4885 |
| US-20180194738-A1 | PARG INHIBITORY COMPOUNDS | PARG, PARP11, PARP16 | TDP1 223/4885SMN1; SMN2 3372/4885TSHR 3689/4885 |
| US-20250333399-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | FGFR1, FGFR2, FGFR3 | TDP1 2063/4885SMN1; SMN2 3037/4885TSHR 1346/4885 |
| US-12129236-B2 | PARG inhibitory compounds | PARP11, PARG, PARP16 | TDP1 233/4885SMN1; SMN2 3672/4885TSHR 3748/4885 |
| US-20200165208-A1 | PARG INHIBITORY COMPOUNDS | PARG, PARP11, PARP16 | TDP1 223/4885SMN1; SMN2 3372/4885TSHR 3689/4885 |
| US-20250340510-A1 | Substituted Phenylbenzenesulfonamide Derivatives and Uses Thereof | TRPM2, TRPM6, TRPM5 | TDP1 1143/4885SMN1; SMN2 74/4885TSHR 4552/4885 |
| US-20250223266-A1 | PARG INHIBITORY COMPOUNDS | PARG, PARP11, PARP16 | TDP1 223/4885SMN1; SMN2 3372/4885TSHR 3689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.